EMERYVILLE, Calif., Nov. 30,
2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq:
BLI), a leader in digital cell biology, today announced its
participation at the upcoming Antibody Engineering &
Therapeutics (AE&T) meeting, being held from December 4 - 8, 2022, in San Diego, California. During the AE&T
meeting, the latest antibody science, technologies, and academic
and industry partners come together to accelerate next-generation
antibodies towards commercial success.
Berkeley Lights will showcase its Beacon® Optofluidic System and
single B-cell antibody discovery workflows at AE&T booth #401.
Meeting participants who visit the Berkeley Lights booth can
receive a demonstration of the Opto® B Discovery workflows on the
Beacon Optofluidic System that enable functional profiling of the B
cell repertoire to discover a broad diversity of antibody hits and
rapidly down-select lead candidates.
In addition, Berkeley Lights will discuss its recently
launched Opto® Memory B Discovery Rabbit workflow, which
Berkeley Lights estimates can:
- Screen approximately 15,000 to 60,000 single cells per
workflow, depending on chip selection and number of chips used per
workflow;
- Identify hundreds to thousands of antigen-specific hits per
workflow; and
- Recover high-quality antibody sequences for the majority of
discovered hits.
Berkeley Lights presentation
Anupam Singhal, Ph.D., Director of Product
Management, Antibody Discovery at Berkeley Lights will present data
on the new Opto Memory B Discovery Rabbit workflow.
Topic: Accessing Broad B Cell Diversity to Rapidly
Identify High-Value Rabbit Monoclonal Antibodies
Date: December 6, 2022, at 12:05
p.m. PT
Abstract: Opto Memory B Discovery Rabbit workflow on the
Beacon optofluidic system enables rapid selection of lead
candidates by function-forward screening of B cells in under one
week. This presentation will introduce Berkeley Lights' newest
antibody discovery workflow, the Opto Memory B Discovery workflow,
and share how customers are using the workflow to screen rabbit
memory B cells to rapidly discover rabbit monoclonal
antibodies.
About Berkeley Light
Berkeley Lights is a leading digital cell biology company focused
on enabling and accelerating the rapid development and
commercialization of biotherapeutics and other cell-based products
for our customers. The Berkeley Lights Platform captures deep
phenotypic, functional, and genotypic information for thousands of
single cells in parallel and can also deliver the live biology
customers desire in the form of the best cells. Our platform is a
fully integrated, end-to-end solution, comprising proprietary
consumables, including our OptoSelect® chips and reagent kits,
advanced automation systems, and application software. We developed
the Berkeley Lights Platform to provide the most advanced
environment for rapid functional characterization of single cells
at scale, the goal of which is to establish an industry standard
for our customers throughout their cell-based product value
chain.
Berkeley Lights' Beacon® and Lightning® systems and
Culture Station™ instrument are FOR RESEARCH USE
ONLY. Not for use in diagnostic procedures.
Forward-Looking Statements
To the extent that
statements contained in this press release are not descriptions of
historical facts regarding Berkeley Lights or its products, they
are forward-looking statements reflecting the current beliefs and
expectations of management. Such forward-looking statements involve
substantial known and unknown risks and uncertainties that relate
to future events, and actual results and product performance could
differ significantly from those expressed or implied by the
forward-looking statements. Berkeley Lights undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties relating to
the Company's growth and continual evolution see the statements in
the "Risk Factors" sections, and elsewhere, in our filings with the
U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/berkeley-lights-to-showcase-its-new-beacon-system-workflow-to-access-broad-b-cell-diversity-to-rapidly-identify-high-value-rabbit-monoclonal-antibodies-at-2022-antibody-engineering--therapeutics-conference-301690279.html
SOURCE Berkeley Lights, Inc.
